Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van JNJ-95566692 bij deelnemers met non-Hodgkin lymfoïde maligniteiten

2 november 2026 bijgewerkt door: Janssen Research & Development, LLC

Een fase 1, first-in-human studie van een nieuw CD79bxCD20xCD3 trispecifiek antilichaam in B-cel non-Hodgkin lymfoïde maligniteiten (NHL's)

The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

340

Fase

  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Clayton, Australië, 3168
        • Werving
        • Monash Medical Centre
      • Melbourne, Australië, 3000
        • Werving
        • Peter MacCallum Cancer Centre
      • North Ryde, Australië, 2109
        • Werving
        • Macquarie University Hospital
      • Randwick, Australië, 2031
        • Werving
        • Scientia Clinical Research
      • Edegem, België, 2650
        • Werving
        • UZ Antwerpen
      • Liège, België, 4000
        • Werving
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Lille, Frankrijk, 59000
        • Werving
        • Hopital Claude Huriez
      • Paris, Frankrijk, 75013
        • Werving
        • CHU Pitie Salpetriere
      • Pierre-Bénite, Frankrijk, 69495
        • Werving
        • CHU Lyon Sud
      • Toulouse, Frankrijk, 31100
        • Werving
        • Institut Universitaire du Cancer Toulouse Oncopole
      • Barcelona, Spanje, 8036
        • Werving
        • Hosp. Clinic de Barcelona
      • Barcelona, Spanje, 08035
        • Werving
        • Hosp Univ Vall D Hebron
      • Madrid, Spanje, 28041
        • Werving
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spanje, 28040
        • Werving
        • Hosp Univ Fund Jimenez Diaz
      • Madrid, Spanje, 28050
        • Werving
        • Hosp Univ Hm Sanchinarro
      • Ankara, Turkije (Türkiye), 06200
        • Werving
        • SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
      • Ankara, Turkije (Türkiye), 06620
        • Werving
        • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
      • Antalya, Turkije (Türkiye), 07025
        • Werving
        • Memorial Antalya Hastanesi Faz 1 Klinik Arastirma Merkezi
      • Istanbul, Turkije (Türkiye), 34010
        • Werving
        • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 and no other approved therapies available that would be more appropriate in the investigator's judgment. -Histologic documentation of the following large B-cell lymphomas: -diffuse large B-cell lymphoma not otherwise specified (NOS), -T-cell/histiocyte-rich large B-cell lymphoma, -diffuse large B-cell lymphoma/high grade B-cell lymphoma with MYC and BCL2 rearrangements, -large B-cell lymphoma with IRF4 rearrangement, -high grade B-cell lymphoma with 11q aberrations, -Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma, -diffuse large B-cell lymphoma associated with chronic inflammation, -primary large B-cell lymphoma of immune privileged sites, -primary cutaneous diffuse large B-cell lymphoma-leg type , -primary mediastinal large B-cell lymphoma, -high-grade B-cell lymphoma NOS, -transformations of indolent B-cell lymphoma (For US sites). -Other B-cell NHL may be enrolled based on emerging data in specific cohorts as stipulated by study evaluation team (SET)
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Participants must have measurable disease as defined by the disease criteria (Lugano criteria)
  • While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate gametes (that is, eggs or sperm) or freeze for future use for the purposes of assisted reproduction; and wear an external condom; -Participants of childbearing potential must have a negative highly sensitive (for example, beta [β]-human chorionic gonadotropin) pregnancy test at screening and within 24 hours before the first dose of study treatment and agree to further pregnancy tests, -For Arm E ONLY: Practice 2 methods of reliable birth control simultaneously, including 1 highly effective form of contraception and 1 additional effective contraceptive method., -Participants on Arms C-G should also follow the pregnancy and contraception restrictions in the respective local corresponding product label

Exclusion Criteria:

  • Known active central nervous system involvement (CNS) or leptomeningeal involvement
  • Prior solid-organ transplantation
  • Malignancy diagnosis other than the disease under study within 1 year prior to the first dose of the study treatment; exceptions are squamous and basal cell carcinoma of the skin, carcinoma in situ of the cervix and any malignancy that is considered cured or has minimal risk of recurrence within 1 year of first dose of the study treatment in the opinion of both the investigator and sponsor's medical monitor
  • Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (for example, methotrexate or tacrolimus) within 3 months prior to first dose of study treatment
  • Toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia, vitiligo, peripheral neuropathy, or Grade <=2 endocrinopathies that are stable on hormone replacement)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm A: JNJ-95566692

Participants will receive escalating doses of JNJ-95566692 in Part 1 (Dose escalation) to determine the putative recommended Phase 2 doses (RP2D[s]) and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK (pharmacokinetic), pharmacodynamic (PD) and clinical activity.

JNJ-95566692 will be administered subcutaneously.

Experimenteel: Arm B: JNJ-95566692 in combination with JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 in combination with JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 in combination with JNJ-87801493 at the putative RP2D(s) determined in Part 1 to further characterize safety, PK, PD and clinical activity.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Experimenteel: Arm C: JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493

Participants will receive escalating doses for JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and loncastuximab tesirine with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Loncastuximab tesirine will be administered intervenously.

Experimenteel: Arm D: JNJ-95566692 and R-GemOx with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and R-GemOx (rituximab, gemcitabine, oxaliplatin) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-GemOx with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.

Gemcitabine will be administered intravenously.

Oxaliplatin will be administered intravenously.

Experimenteel: Arm E: JNJ-95566692 and lenalidomide with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and lenalidomide with or without JNJ-87801493 in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and lenalidomide with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

Lenalidomide will be administered orally.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Experimenteel: Arm F: JNJ-95566692 and R-CHOP with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and R-CHOP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

Cyclophosphamide will be administered intravenously.

Prednisone will be administered orally.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.

Doxorubicin will be administered intravenously.

Vincristine will be administered intravenously.

Experimenteel: Arm G: JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493

Participants will receive escalating doses of JNJ-95566692 and Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) with or without JNJ-87801493 followed by the target dose in Part 1 (Dose escalation) to determine the putative RP2D[s] and dosing schedule(s). Participants in Part 2 (Dose expansion) will receive JNJ-95566692 and Pola-R-CHP with or without JNJ-87801493 at the putative RP2D(s) determined in Part 1.

Cyclophosphamide will be administered intravenously.

Prednisone will be administered orally.

JNJ-87801493 will be administered subcutaneously.

JNJ-95566692 will be administered subcutaneously.

Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.

Doxorubicin will be administered intravenously.

Polatuzumab vedotin will be administered intravenously.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Part 1 and 2: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by Severity
Tijdsspanne: Approximately 2 years and 8 months

An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product. Severity for AEs will be specified as per: National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades which are Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (potentially life-threatening) and Grade 5 (death related to adverse event). SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

Approximately 2 years and 8 months
Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)
Tijdsspanne: Approximately 2 years and 8 months

Number of participants with DLTs for JNJ-95566692 (arm A), in combination with JNJ-87801493 (arm B) and in arms C to G will be reported. The DLTs are drug-related toxicities and are defined as any of the following: fatal toxicity, high grade non-hematologic toxicity, or hematologic toxicity.

Approximately 2 years and 8 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Serum Concentration for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

Serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be assessed using a validated assay method.

Approximately 2 years and 8 months
Area Under the Curve During a Dosing Interval (AUCtau) in JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

AUC tau is defined as area under the serum concentration-time curve during a dosing interval (tau).

Approximately 2 years and 8 months
Maximum Serum Concentration (Cmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

Cmax for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Minimum Serum Concentration (Cmin) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

Cmin for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Area Under the Curve (AUC[0-t]) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

AUC(0-t) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Half-life (t1/2) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

Half-life (t1/2) for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Time to Reach Cmax (Tmax) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

Tmax is the time to reach maximum observed serum concentration for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Apparent Total Body Clearance (CL/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

CL/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Apparent Volume of Distribution (V/F) for JNJ-95566692 (Arms A-G) And JNJ-87801493 (Arms B-G)
Tijdsspanne: Approximately 2 years and 8 months

V/F for JNJ-95566692 (Arms A-G) and JNJ-87801493 (Arms B-G), where applicable will be reported.

Approximately 2 years and 8 months
Number of Participants with Anti-JNJ-95566692 Antibodies in Arms A to G
Tijdsspanne: Approximately 2 years and 8 months

Participants with presence of antibodies binding to JNJ-95566692 in arm A to G will be reported.

Approximately 2 years and 8 months
Number of Participants with Anti-JNJ-87801493 Antibodies in Arms B to G
Tijdsspanne: Approximately 2 years and 8 months

Participants with presence of antibodies binding to JNJ-87801493 in arm B to G (as appropriate) will be reported.

Approximately 2 years and 8 months
Part 2: Overall Response for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Tijdsspanne: Approximately 2 years and 8 months

Overall response is defined as a best response of partial response (PR) or better as assessed by the investigator according to standard response criteria per Lugano.

Approximately 2 years and 8 months
Part 2: Complete Response (CR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Tijdsspanne: Approximately 2 years and 8 months

Complete response (CR) is defined as a best response of CR as assessed by the investigator according to standard response criteria per Lugano.

Approximately 2 years and 8 months
Part 2: Time to Response (TTR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Tijdsspanne: Approximately 2 years and 8 months

TTR is defined for participants who achieved a response of PR or better as the time from the first dose of study treatment to the first response of PR or better.

Approximately 2 years and 8 months
Part 2: Duration of Response (DOR) for JNJ-95566692 (Arm A), in Combination With JNJ-87801493 (Arm B) And for JNJ-95566692 ± JNJ-87801493 with Combination Therapies In Arms C to G
Tijdsspanne: Approximately 2 years and 8 months

DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease, initiation of a new systemic anti-cancer therapy or death.

Approximately 2 years and 8 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 januari 2026

Primaire voltooiing (Geschat)

31 augustus 2028

Studie voltooiing (Geschat)

31 oktober 2029

Studieregistratiedata

Eerst ingediend

15 december 2025

Eerst ingediend dat voldeed aan de QC-criteria

15 december 2025

Eerst geplaatst (Werkelijk)

29 december 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

3 november 2026

Laatste update ingediend die voldeed aan QC-criteria

2 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 95566692LYM1001
  • 95566692LYM1001 (Andere identificatie: Janssen Research & Development, LLC)
  • 2025-523297-16-00 (Register-ID: EUCT number)
  • 2025 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren